Dan Strange

Dan Strange currently serves as the Chief Technology Officer at Cellular Origins, a TTP Company, where the focus is on advancing scalable and efficient manufacturing of cell and gene therapies through innovative technology solutions. With prior experience as an Employee Trustee Director at TTP Group, Dan played a key role in representing employee interests within the company. Dan's background includes significant contributions to future cell therapy automation at TTP plc, as well as early experience as a Biomedical Engineer at Columna Pty Ltd, where work involved the development of a minimally invasive treatment for back pain. Dan holds a Ph.D. in Tissue Engineering and an M.A./M.Eng. in Engineering for the Life Sciences from the University of Cambridge.